BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BeyondBio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies BeyondBio's drugs run\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06885567-756@assetmemo.bio
DTSTAMP:20261121T005230Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:BEY2153: Phase 2 readout est. (NCT06885567)
DESCRIPTION:BEY2153\, phase 2\, Alzheimer's Disease.\nStudy: A Phase 2 Stud
 y to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Al
 zheimer's Disease\nEstimated primary completion: July 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bey2153#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06885567
URL:https://assetmemo.bio/drug/bey2153#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
